Floatz logo

Darifenacin

Overactive Bladder

US Department of Veterans AffairsSmall moleculePhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
81/ 100

Competitive context

14 Active assets in the Overactive Bladder cohort.

Asset / SponsorPhaseRating
Mirabegron
VA Office of Research and Development
Phase 4BB
TROSPIUM
Allergan
Phase 4BB
Nabiximols
Jazz Pharmaceuticals
Phase 3BB
SOLIFENACIN
VA Office of Research and Development
Phase 4B
Oxybutynin
University of California, Davis
Phase 3B

View all 22 →

Same molecule, other indications

Darifenacin is also rated in:

amyotrophic lateral sclerosisDormant
CCC
Indicative ·
51 / 100
View asset →
multiple sclerosisDormant
CCC
Indicative ·
48 / 100
View asset →
Parkinson diseaseDormant
D
Indicative ·
30 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →